Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Colorectal Neoplasms 2Sarcoma, Kaposi 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma 1Hematologic Neoplasms 1Graft vs Host Disease 1Colorectal Cancer Metastatic 1

Interventions

Cyclophosphamide 297Rituximab 272Etoposide 149Filgrastim 142fludarabine phosphate 120Cytarabine 109Vincristine 107Melphalan 102Radiotherapy 101Doxorubicin 97Peripheral Blood Stem Cell Transplantation 93Methotrexate 91fludarabine 86Prednisone 86Busulfan 86Tacrolimus 66Mycophenolic Acid 62Granulocyte Colony-Stimulating Factor 60Antilymphocyte Serum 58Dexamethasone 57Whole-Body Irradiation 55Carmustine 54Bortezomib 45Cyclosporine 44Lenalidomide 41Methylprednisolone 40sargramostim 39Bendamustine Hydrochloride 37ibritumomab tiuxetan 34Ifosfamide 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma × Maraviroc × Clear all
NCT02799888 2016-06-15

Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation

Affiliated Hospital to Academy of Military Medical Sciences

Phase 2 Unknown
40 enrolled
LymphoidMyeloid

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡